Watchlist Price Alert

BioCryst Pharmaceuticals ... (BCRX)

NASDAQ: BCRX · Real-Time Price · USD

11.06

2.13 (23.85%)

At close: May 05, 2025, 3:59 PM

11.01

-0.45%

After-hours: May 05, 2025, 07:59 PM EDT

23.85% (1D)

Bid	11.01
Market Cap	2.31B
Revenue (ttm)	450.71M
Net Income (ttm)	-88.88M
EPS (ttm)	-0.43
PE Ratio (ttm)	-25.72
Forward PE	37.91
Analyst	Buy

Ask	11.13
Volume	23,697,317
Avg. Volume (20D)	3,686,950
Open	9.85
Previous Close	8.93
Day's Range	9.60 - 11.11
52-Week Range	4.75 - 11.11
Beta	1.75

About BCRX

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 4, 1994

Employees 580

Stock Exchange NASDAQ

Ticker Symbol BCRX

Website https://www.biocryst.com

Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for BCRX stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 35.62% from the latest price.

Stock Forecasts

Earnings Surprise

New

BioCryst Pharmaceuticals has released their quartely earnings on May 5, 2025:

Revenue of $145.53M exceeds estimates by $17.74M, with 56.89% YoY growth.

EPS of 0 exceeds estimates by 0.05, with 100.00% YoY growth.

Next Earnings Release

BioCryst Pharmaceuticals Inc. is scheduled to release its earnings on May 5, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 day ago New

+23.52%

BioCryst Pharmaceuticals shares are trading higher... Unlock content with Pro Subscription

2 months ago

-9.99%

BioCryst Pharmaceuticals shares are trading lower after the company reported Q4 financial results and missed its adjusted EPS estimate.

News

21 hours ago · benzinga.com

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

BioCryst Pharmaceuticals, Inc. BCRX on Monday reported first-quarter sales of $145.50 million, up 52.7% year over year, beating the consensus of $126.87 million.

1 day ago · seekingalpha.com

BioCryst: Strong Opportunity For A Double With A Proven Therapy

BioCryst Pharmaceuticals' flagship product ORLADEYO shows remarkable growth, maintaining a persistent upward trajectory since its launch in 2020, and is expected to continue into 2025. Despite heavy r...

1 day ago · seekingalpha.com

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer ...

17 hours ago · zacks.com

BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1

BioCryst Pharmaceuticals (BCRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.17 per share a year ago.

1 week ago · zacks.com

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago · zacks.com

How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry

BioCryst (BCRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

2 months ago · zacks.com

BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for BioCryst (BCRX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Str...

2 months ago · zacks.com

Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher

After losing some value lately, a hammer chart pattern has been formed for BioCryst (BCRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisi...

2 months ago · zacks.com

Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 84.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the posit...

2 months ago · seekingalpha.com

BioCryst: Orladeyo's Expansion Is Just Getting Started

BioCryst Pharmaceuticals, a rare disease biotech, shows strong revenue growth from ORLADEYO, a healthy cash position, and a promising pipeline, making it an attractive investment. Despite a net loss, ...

Load More News